Anticonvulsant effects of iridoid glycosides fraction purified from Feretia apodanthera Del. (Rubiaceae) in experimental mice models of generalized tonic-clonic seizures

Table 4 Acute toxicity of the IGEFA administered orally to different groups of mice

Treatment	Dose (mg/kg)	Sex	D/T	Mortality latency (h)	Toxic symptoms
Vehicle	–	Male	0/5	–	None
Vehicle	–	Female	0/5	–	None
IGEFA	5	Male	0/5	–	None
IGEFA	5	Female	0/5	–	None
IGEFA	15	Male	0/5	–	None
IGEFA	15	Female	0/5	–	None
IGEFA	30	Male	0/5	–	None
IGEFA	30	Female	0/5	–	None
IGEFA	90	Male	0/5	–	None
IGEFA	90	Female	0/5	–	None
IGEFA	180	Male	0/5	–	None
IGEFA	180	Female	0/5	–	None
IGEFA	360	Male	0/5	–	None
IGEFA	360	Female	0/5	–	None
IGEFA	720	Male	3/5	36–48	Hypoactivity, piloerection, salivation
IGEFA	720	Female	5/5	36–48	Hypoactivity, piloerection, salivation
IGEFA	1440	Male	4/5	24–36	Hypoactivity, piloerection, salivation
IGEFA	1440	Female	5/5	24–36	Hypoactivity, piloerection, salivation
IGEFA	2880	Male	5/5	24–36	Hypoactivity, piloerection, salivation
IGEFA	2880	Female	5/5	36–48	Hypoactivity, piloerection, salivation
IGEFA	5760	Male	5/5	36–48	Asthenia, anorexia, salivation, asthenia
IGEFA	5760	Female	5/5	36–48	Asthenia, anorexia, salivation, asthenia

D/T = Dead/Treated mice; None = No toxic symptoms during the observation period; mortality latency = time to death after the oral administration. The IGEFA was two groups of mice. Mice in each group were carefully examined for any signs of toxic (behavioural changes and mortality) for 14 days. Control group received vehicle (10 ml/kg, per os)